文献速递慢阻肺

慢性黏液高分泌对COPD吸入治疗反应的影响:IMPACT试验事后分析

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.
PubMed 文献 · Respirology · 2022-08-15

IMPACT试验事后分析评估慢性黏液高分泌(CMH)状态与COPD治疗反应的关系。10,250例有基线SGRQ数据的患者中62%为CMH+,FF/UMEC/VI较双联疗法显著降低中重度急性加重率,且CMH状态不影响疗效。但CMH+患者中FF/VI较UMEC/VI显著降低加重率,提示双联疗法比较时需考虑CMH。

要点

  • FF/UMEC/VI在CMH+和CMH-患者中均显著降低中重度急性加重率
  • CMH状态不影响FF/UMEC/VI对肺功能和生活质量的改善
  • CMH+患者中FF/VI较UMEC/VI显著降低中重度和重度急性加重率

核心结论

  • FF/UMEC/VI较双联疗法具有有利的获益风险比,且不受CMH状态影响。
  • CMH状态未影响治疗反应、急性加重、肺功能或健康状态。
  • 但CMH在双联疗法比较时产生差异,未来试验设计应考虑CMH影响。

研究设计与样本

  • IMPACT试验的探索性事后分析,患者随机接受FF/UMEC/VI 100/62.5/25 μg、FF/VI 100/25 μg或UMEC/VI 62.5/25 μg每日一次。
  • 意向治疗人群10,355例,其中10,250例报告基线SGRQ数据,CMH+占62%(n=6383)。
  • CMH+定义为圣乔治呼吸问卷(SGRQ)第1和第2题评分为1或2。

主要发现

  • CMH+患者中,FF/UMEC/VI较FF/VI和UMEC/VI显著降低治疗中中重度急性加重率(率比0.87和0.72,p<0.001)。
  • CMH-患者中,FF/UMEC/VI较FF/VI和UMEC/VI显著降低中重度急性加重率(率比0.82和0.80,p<0.001)。
  • CMH+患者中,FF/UMEC/VI较UMEC/VI显著降低重度急性加重率(率比0.62,p<0.05);CMH-患者中率比0.74(p<0.05)。
  • CMH+患者中,FF/VI较UMEC/VI显著降低中重度和重度急性加重率(率比0.83和0.70,p<0.001)。
  • 无论CMH状态,FF/UMEC/VI均显示健康状态和肺功能相似改善。

关键数值与推荐

  • CMH+定义为SGRQ第1和第2题评分为1或2。
  • 中重度急性加重率比较:FF/UMEC/VI vs FF/VI率比0.87(CMH+)和0.82(CMH-);vs UMEC/VI率比0.72(CMH+)和0.80(CMH-),均p<0.001。
  • 重度急性加重率比较:FF/UMEC/VI vs UMEC/VI率比0.62(CMH+)和0.74(CMH-),均p<0.05。
  • CMH+患者中FF/VI vs UMEC/VI中重度和重度急性加重率比0.83和0.70,p<0.001。

临床怎么用

  • FF/UMEC/VI可用于COPD患者 regardless of CMH状态,均能降低急性加重并改善肺功能和生活质量。
  • 在CMH+患者中选择双联疗法时,FF/VI可能较UMEC/VI更有效降低急性加重。
  • 评估COPD治疗反应时需考虑CMH状态对双联疗法比较的影响。

局限性

  • 为事后探索性分析,结果需前瞻性研究验证。
  • CMH定义基于SGRQ问卷第1和第2题,可能受主观因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Chronic mucus hypersecretion (CMH) is a clinical phenotype of COPD. This exploratory post hoc analysis assessed relationship between CMH status and treatment response in IMPACT. METHODS: Patients were randomized to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg, FF/VI 100/25 μg or UMEC/VI 62.5/25 μg and designated CMH+ if they scored 1/2 in St George's Respiratory Questionnaire (SGRQ) questions 1 and 2. Endpoints assessed by baseline CMH status included on-treatment exacerbation rates, change from baseline in trough forced expiratory volume in 1 second, SGRQ total score, COPD Assessment Test (CAT) score, proportion of SGRQ and CAT responders at Week 52 and safety. RESULTS: Of 10,355 patients in the intent-to-treat population, 10,250 reported baseline SGRQ data (CMH+: 62% [n = 6383]). FF/UMEC/VI significantly (p < 0.001) reduced on-treatment moderate/severe exacerbation rates versus FF/VI and UMEC/VI in CMH+ (rate ratio: 0.87 and 0.72) and CMH- patients (0.82 and 0.80). FF/UMEC/VI significantly (p < 0.05) reduced on-treatment severe exacerbation rates versus UMEC/VI in CMH+ (0.62) and CMH- (0.74) subgroups. Similar improvements in health status and lung function with FF/UMEC/VI were observed, regardless of CMH status. In CMH+ patients, FF/VI significantly (p < 0.001) reduced on-treatment moderate/severe and severe exacerbation rates versus UMEC/VI (0.83 and 0.70). CONCLUSION: FF/UMEC/VI had a favourable benefit: risk profile versus dual therapies irrespective of CMH status. The presence of CMH did not influence treatment response or exacerbations, lung function and/or health status. However, CMH did generate differences when dual therapies were compared and the impact of CMH should be considered in future trial design.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Thompson, Criner, Dransfield, et al. Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial. Respirology. 2022. PMID: 35970518. doi:10.1111/resp.14339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。